Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — Corporate Update (May 2019)
26 slides from Precigen's corporate update, May 9, 2019
Slide 1: Intrexon Health Overview May 2019
Intrexon Health Overview May 2019 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements © 2019 Intrexon Corp. All rights reserved. Intrexon Corporation is sharing the following materials for informational purposes only. Such materials do not constitute an offer to sell or the solicitation of an offer to buy any securities of Intrexon. Any offer and sale of In
Slide 3: Intrexon Health Investment Overview
Intrexon Health Investment Overview Possessing the broadest and deepest gene and cell therapy technologies and capabilities Addressing unmet medical needs with therapeutics that are Targeted, Controllable, and Multigenic Eight clinical stage assets across diverse indications, more coming to the clin
Slide 4: Board of Directors
Board of Directors Randal J. Kirk Chairman Chairman & CEO of Intrexon Former Chairman/CEO of New River Pharmaceuticals, Inc. and Chairman of Clinical Data, Inc. Cesar Alvarez Senior Chairman of Greenberg Traurig Recognized as one of the “100 Most Influential Lawyers in America” Vinita Gupta CEO of L
Slide 5: Executive Leadership
Executive Leadership Co-Founder & COO of General Injectables and Vaccines (now the medical business of Henry Schein) Co-founder and first President of King Pharmaceuticals (now part of Pfizer) Board member and largest shareholder of Scios, Inc. (now part of Johnson & Johnson) Founder, Chairman, CEO
Slide 6: Intrexon Health's Integrated GeneRx Platform
Intrexon Health’s Integrated GeneRx Platform AttSite-mediated Genome Integration Library of serine recombinases for integrating large DNA payloads into cell lines RheoSwitch-mediated Transcription Control Clinically demonstrated small molecule-based inducible control over timing and dose of therapeu
Slide 7: Intrexon Therapeutics are Targeted, Controllable, Multigenic
Intrexon Therapeutics are Targeted, Controllable, Multigenic Intrexon’s technology and expertise facilitate the creation of sophisticated solutions designed to treat complex diseases Targeted: We employ cell and genome delivery systems designed to match disease and/or injury-related specifications.
Slide 8: Intrexon Health Spans Broad Therapeutic Areas
Intrexon Health Spans Broad Therapeutic Areas Precision therapeutics Immuno-oncology Autoimmunity Infectious Diseases Autoimmunity Inflammation Gastrointestinal Disorders Allergy Oral Mucositis RDEB Localized Scleroderma Friedreich's Ataxia Exosome Delivery Platform Others - undisclosed Regen. Med.
Slide 9: Eight Therapeutic Candidates in Clinical Development
Therapeutic Area Disease Target Therapeutic Candidate Preclinical Phase I Phase II Phase III Oncology [Precigen] Ovarian Cancer PRGN-3005 Oncology [Precigen] Relapsed/Refractory AML Higher Risk MDS PRGN-3006 Oncology [Precigen] Relapsed/Refractory AML INXN-3004 Cardiac Disease [Triple-Gene] Heart Fa
Slide 10: Precigen's Pipeline Offers Rapid Value Creation
Precigen’s Pipeline Offers Rapid Value Creation and Potential for Novel Combinations Precigen pipeline as of February 2019 TA Product Platform Indication Discovery Preclinical Phase I Immuno-oncology PRGN-3006 UltraCAR-T AML, MDS INXN-3004 Viral CAR-T AML PRGN-3005 UltraCAR-T Ovarian Cancer PRGN-300
Slide 11: Precigen's UltraCAR-T Platform Advantages
Precigen’s UltraCAR-T™ Platform Advantages: Enhanced Potency, Safety, and Scalability CAR mbIL-15 Kill Switch CAR – targeting for tumor types, optimized designs mbIL15 – improves potency, no ex vivo expansion needed Kill switch – designed to improve safety, can selectively deplete cell therapy Multi
Slide 12: Transformative UltraCAR-T Candidates PRGN-3005 and PRGN-3006
Transformative UltraCAR-T™ Candidates PRGN-3005 and PRGN-3006 Status FDA IND clearance in Feb ‘19 Phase1 study to evaluate safety and maximal tolerated dose Study in collaboration with University of Washington Patient Population Advanced stage platinum resistant ovarian cancer 300k diagnosed annuall
Slide 13: UltraCAR-T Platform Enables Rapid Manufacturing
UltraCAR-T™ Platform Enables Rapid Manufacturing Electroporation Leukapheresis UltraCAR-T™ Infusion Less than two days Leukapheresis and T cell isolation from patient UltraCAR-T™ cells expand in patients UltraCAR-T™ cells Electroporation of non-viral Sleeping Beauty for expression of CAR, mbIL15 and
Slide 14: Multigenic Candidate Displays Robust Biofunctional Activity
Multigenic Candidate Displays Robust Biofunctional Activity Precigen’s multigenic candidate PRGN-5001 provides improved T cell activation in vitro and anti-tumor response in mice compared to approved anti-PD-1 checkpoint inhibitor Improved T cell activation Improved anti-tumor activity
Slide 15: Vaccine Candidates Generate Superior Immune Responses
Vaccine Candidates Generate Superior Immune Responses Novel antigen designs for infectious disease vaccine candidates produce robust antigen-specific response AdenoVerse™ vaccine (PRGN-2013) produces superior immune response Precigen AdenoVerse™ vaccine candidates and technology platform generate su
Slide 16: Autoimmunity Candidate Demonstrates Potent Bioactivity
Autoimmunity Candidate Demonstrates Potent Bioactivity Precigen’s autoimmunity asset PRGN-3009 demonstrated potent suppression of effector cell function in vitro PRGN-3009 PRGN-3009 Suppression of effector T cell proliferation Novel multigenic approach for treatment of autoimmune disorders with unme
Slide 17: ActoBiotics Platform – A Novel Class of Oral Biotherapeutics
ActoBiotics® Platform – A Novel Class of Oral Biotherapeutics ActoBiotics® is a fully integrated, cost-effective & unique food microbe-based delivery platform for therapeutics Potential for superior efficacy and safety through oral or local targeted delivery Platform based on using Lactococcus lacti
Slide 18: AG019 and AG013 Trials Ongoing
AG019 Ib/IIa trial in the treatment of early onset type 1 diabetes is ongoing and patient enrollment is proceeding in the US and Europe Collaborator Oragenics, Inc. continues patient enrollment in the Phase IIb trial for AG013 in the treatment for oral mucositis ANTIGEN-SPECIFIC TREGS MIGRATE TO INF
Slide 19: Triple-Gene LLC: First Triple Gene Drug to Target Heart Failure
We are continuing patient enrollment and dosing in Phase I trial of INXN-4001, an investigational drug which is the world’s first triple gene drug candidate to target heart failure, the leading cause of death in humans Triple-Gene LLC: First Triple Gene Drug to Target Heart Failure in Clinic Angioge
Slide 20: Preliminary Data Suggests Improvements in Cardiac Performance
Preliminary Data Suggests Improvements in Cardiac Performance Characteristic Subject 01-01 Subject 01-03 Subject 01-04 Baseline 10% 10% 10% 90 Days 20% 15% 35% 6 months 20% - 40% Left Ventricular Ejection Fraction (LVEF) LVEF refers to the amount of blood being pumped out of the left ventricle each
Slide 21: Exemplar: Advancing Swine for Regenerative Medicine and Research
Exemplar: Advancing Swine for Regenerative Medicine and Research Focus on regenerative medicine continues with Exemplar and the Mayo Clinic launching a joint venture, Cytotheryx, to develop high-quality source of human liver cells to advance medical research and address an estimated $250 million ann
Slide 22: Cannabinoids for Medical Use
Cannabinoids for Medical Use Intrexon’s proprietary yeast strains enable a transformative process for robust production of cannabinoids with consistent yield and purity Platform is designed to enable production of multiple target cannabinoids Intrexon Labs Hungary: Robust Microbial Production of The
Slide 23: Diverse Delivery Modalities for Innovative Therapeutics
Diverse Delivery Modalities for Innovative Therapeutics FCX-007: An autologous dermal fibroblast genetically modified to express functional Type VII collagen (COL7) that is missing or deficient in patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) is currently in a Phase 1/2 clinical tr
Slide 24: Upcoming Milestones
Upcoming Milestones 2Q 2019 2Q 2019 2019 2Q 2019 2Q 2019 2Q 2019 3Q 2019 Anticipated Timing First patient dosing in Phase 1 clinical trial for PRGN-3005 UltraCAR-T™ First patient dosing in Phase 1 clinical trial for PRGN-3006 UltraCAR-T™ Completion of patient enrollment for Phase Ib/IIa for AG019 IN
Slide 25: Intrexon Bioengineering
Intrexon Bioengineering Elite Bovine Genetics and Embryo Production Land-based Sustainable Aquaculture Non-browning apples Microbial Production of Fuels and Chemicals Precision Genetics for Sustainable Crop Production Insect Protein for Animal Feed Self-limiting Insect Control Ag Bio Division Indust
Slide 26: Intrexon Corporate Highlights
Intrexon Corporate Highlights We are realigning to focus on Healthcare by forming Intrexon Health and Intrexon Bioengineering while streamlining management We believe the company will end the year with approximately the same net cash and short-term investment position that it held on April 3, 2019,